ArticleClinical journal of gastroenterology2025
A case of esophageal cancer with superior vena cava syndrome treated with chemotherapy via a central venous port placed by translumbar approach.
Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Superior vena cava syndrome (SVCS) is a serious condition that complicates the placement of central venous access port (CV port) in cancer patients. This report highlights the successful placement of a CV port by translumbar approach in a patient with advanced esophageal carcinoma complicated by SVCS. The patient was an 80-year-old woman whose tumor had invaded the superior vena cava (SVC) through the azygos vein, necessitating stent placement in the SVC. Subsequently, a CV port was implanted in the inferior vena cava using a translumbar approach, allowing the initiation of chemotherapy. The patient underwent nine cycles of FOLFOX followed by four cycles of nivolumab. To address worsening dysphagia, an esophageal stent was placed, disease progression was confirmed during treatment. The patient then transitioned to best supportive care. The patient passed away 432 days after the CV port placement. Notably, no port-related complications were observed throughout the course of treatment, underscoring the feasibility and safety of the translumbar approach in patients with SVCS.
Indexed as
Identifiers
40167979What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.